Comparative Pharmacology
Head-to-head clinical analysis: MIOCHOL versus MIOCHOL E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIOCHOL versus MIOCHOL E.
MIOCHOL vs MIOCHOL-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miochol (acetylcholine chloride) is a direct-acting cholinergic agonist that binds to and activates muscarinic receptors, causing miosis (pupil constriction) and contraction of the ciliary muscle, thereby facilitating intraocular surgery.
Cholinergic agonist: mimics acetylcholine at muscarinic receptors, causing contraction of the sphincter muscle of the iris (miosis) and ciliary muscle (accommodation).
Intraocular injection of 0.5 mL of a 1:100 (10 mg/mL) solution into the anterior chamber to achieve miosis within seconds.
Intracameral injection: 0.5 mL of reconstituted solution (containing 1:100 acetylcholine chloride) instilled into the anterior chamber of the eye after lens delivery and before wound closure. Single dose per procedure; repeat if necessary, but not within 24 hours.
None Documented
None Documented
Plasma half-life is approximately 2-3 minutes due to rapid enzymatic hydrolysis; clinical effect is brief and intraocular effect lasts only during the surgical procedure.
Terminal elimination half-life of acetylcholine is approximately 1-2 minutes due to rapid hydrolysis by acetylcholinesterase; in the eye, the miotic effect lasts about 4-6 hours.
Miochol (acetylcholine chloride) is rapidly hydrolyzed by acetylcholinesterase in the blood and tissues; less than 1% is excreted unchanged in urine. No significant biliary or fecal elimination.
Renal (primarily as unchanged drug and metabolites via glomerular filtration and tubular secretion) ~90%; fecal ~10%.
Category C
Category C
Ophthalmic Miotic
Ophthalmic Miotic